Skip to content
Clinical Research Made Simple

Clinical Research Made Simple

Trusted Resource for Clinical Trials, Protocols & Progress

  • Home
  • Audit Findings
    • General Audit Findings in Clinical Trials
    • Investigator Site-Level Audit Findings
    • Sponsor & CRO-Level Audit Findings
    • Trial Master File (TMF) & eTMF Audit Findings
    • Informed Consent Audit Findings
    • Safety Reporting Audit Findings
    • Data Integrity & EDC Audit Findings
    • GCP Training & Compliance Audit Findings
    • Clinical Trial Supply & IMP Audit Findings
    • Ethics Committee / IRB Audit Findings
    • CAPA & Inspection Readiness Audit Findings
    • Case Studies & Trends in Audit Findings
  • Audits, CAPA & Deviations
    • CRO Audit Oversight
    • CAPA Management in CROs
    • Deviation Handling in CROs
    • Inspection Readiness for CROs
    • Data Integrity & Systems Oversight
    • Training & Quality Culture in CROs
  • SOPs for GCP
    • Global SOPs (Applicable to all Agencies)
    • SOP for IDE/Device
    • FDA — Unique SOPs (United States)
    • EMA — Unique SOPs (European Union)
    • CDSCO/DCGI – Unique SOPs (India)
    • WHO – Unique SOPs
    • ICH – Unique SOPs
    • MHRA — Unique SOPs (United Kingdom)
    • Health Canada — Unique SOPs (Canada)
    • PMDA — Unique SOPs
    • TGA — Unique SOPs
    • NMPA — Unique SOPs
    • ANVISA — Unique SOPs
    • Swiss Medic — Unique SOPs
    • Medsafe/HDEC — Unique SOPs (New Zealand)
  • US Regulatory Submissions
  • Toggle search form

SOP for Portuguese Consent and Cultural/Ethical Considerations

Posted on August 26, 2025 digi By digi

SOP for Portuguese Consent and Cultural/Ethical Considerations

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/portuguese-consent-and-cultural-ethical-considerations”
},
“@id”: “https://www.clinicalstudies.in/portuguese-consent-and-cultural-ethical-considerations”,
“headline”: “SOP for Portuguese Consent and Cultural/Ethical Considerations”,
“name”: “SOP for Portuguese Consent and Cultural/Ethical Considerations”,
“description”: “Comprehensive SOP detailing requirements for Portuguese informed consent and addressing cultural and ethical considerations in Brazilian clinical trials to ensure compliance with ANVISA and CONEP regulations.”,
“keywords”: “Portuguese consent SOP, informed consent translation Brazil, SOP for cultural considerations Brazil, trial consent bilingual SOP, patient comprehension SOP Brazil, ANVISA consent compliance, SOP for Portuguese ICFs, cultural safety clinical trials Brazil, SOP for ethics submissions Brazil, subject comprehension SOP Brazil, SOP for back-translation ICF, regulatory submissions ANVISA SOP, SOP for bilingual trial documents Brazil, clinical trial consent governance Brazil, SOP for site investigator consent, SOP for sponsor obligations consent Brazil, Portuguese patient information sheet SOP, SOP for subject-facing documents Brazil, SOP for consent QA review, inspection readiness consent SOP Brazil, SOP for document localization Brazil, CRO responsibilities consent SOP, SOP for subject re-consent Brazil, SOP for informed consent narratives

Brazil, SOP for translation vendor governance Brazil”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Published on 25/12/2025

Portuguese Consent and Cultural/Ethical Considerations SOP

Department Clinical Research
SOP No. CS/ANVISA-CONSENT/183/2025
Supersedes N.A.
Page No. 1 of 22
Issue Date 28/08/2025
Effective Date 05/09/2025
Review Date 05/09/2027

Table of Contents

Toggle
  • Purpose
  • Scope
  • Responsibilities
  • Accountability
  • Procedure
  • Abbreviations
  • Documents
  • References
  • Approval
  • Annexures
  • Revision History

Purpose

The purpose of this SOP is to define standardized procedures for developing, translating, and administering Portuguese language informed consent forms (ICFs) and ensuring that cultural and ethical considerations are addressed in clinical trials conducted in Brazil. It aligns with ANVISA, CONEP, and ICH GCP requirements, ensuring participants are provided with accurate and understandable information.

See also  SOP for HDEC Ethics Submissions and Conditions of Approval

Scope

This SOP applies to all clinical trials conducted in Brazil where participants require informed consent in Portuguese. It covers translation, back-translation, cultural adaptation, ethics submissions, site responsibilities, subject re-consent, and record-keeping. It is applicable to sponsors, CROs, investigators, and translation vendors involved in Brazilian clinical trials.

Responsibilities

  • Sponsor: Ensures Portuguese ICFs are available, approved by CONEP, and implemented before trial initiation.
  • Principal Investigator (PI): Conducts the consent process, ensures participant comprehension, and maintains signed ICFs at the site.
  • Clinical Research Coordinator (CRC): Assists PI in the consent process, maintains records, and ensures participants are provided with subject-facing documents in Portuguese.
  • Regulatory Affairs (RA): Submits Portuguese ICFs and supporting documentation to ANVISA and CONEP.
  • Quality Assurance (QA): Verifies accuracy of translations and ensures inspection readiness.
  • Translation Vendor: Provides certified translations and back-translations for ICFs and subject materials.

Accountability

The Sponsor is accountable for ensuring that consent documents are available in Portuguese and ethically sound. The PI is accountable for ensuring participant comprehension and that signed ICFs are properly documented.

Procedure

1. Translation of Informed Consent Documents

  1. Engage certified medical translators for Portuguese translation of ICFs and subject materials.
  2. Perform back-translation into English to confirm accuracy and consistency with original documents.
  3. File Certificate of Translation Accuracy in TMF.
See also  SOP for Data Coding, Cleaning, and Quality Checks

2. Cultural and Ethical Adaptation

  1. Ensure consent documents use culturally sensitive language and avoid medical jargon.
  2. Adapt terminology to align with Brazilian cultural norms and literacy levels.
  3. Engage Ethics Committees (CONEP) to review cultural appropriateness of translated ICFs.

3. Informed Consent Process

  1. Provide subjects with Portuguese ICFs prior to trial enrollment.
  2. Allow sufficient time for subjects to read, discuss, and ask questions.
  3. Ensure comprehension by asking subjects to explain trial risks and procedures in their own words.

4. Ethics and Regulatory Submissions

  1. Submit Portuguese ICFs to CONEP and ANVISA along with the protocol package.
  2. File ethics approval letters and acknowledgment receipts in TMF and ISF.

5. Re-Consent

  1. Implement re-consent procedures in Portuguese when protocol amendments significantly impact subject rights, safety, or trial procedures.

6. Archiving

  1. Maintain signed ICFs, translation logs, and approval documents in TMF and ISF.
  2. Archive consent-related records for 15 years or as per Brazilian requirements.

Abbreviations

  • ANVISA: Agência Nacional de Vigilância Sanitária
  • CONEP: Comissão Nacional de Ética em Pesquisa
  • ICF: Informed Consent Form
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • RA: Regulatory Affairs
  • QA: Quality Assurance
  • TMF: Trial Master File
  • ISF: Investigator Site File

Documents

  1. Translation Requirement Log (Annexure-1)
  2. Certificate of Translation Accuracy (Annexure-2)
  3. Consent Process Documentation Log (Annexure-3)
See also  SOP for EudraVigilance SUSAR/ICSR Submissions and Follow-Ups

References

  • ANVISA — National Health Surveillance Agency
  • CONEP — National Commission for Ethics in Research
  • ICH E6(R2) Good Clinical Practice

Version: 1.0

Approval

Prepared By Checked By Approved By
Name: Rajesh Kumar
Date: 20/08/2025
Signature: __________
Name: Sunita Reddy
Date: 22/08/2025
Signature: __________
Name: Dr. Meera Iyer
Date: 28/08/2025
Signature: __________

Annexures

Annexure-1: Translation Requirement Log

Date Document Status Reviewer
05/08/2025 Portuguese ICF v1.0 Completed Rajesh Kumar

Annexure-2: Certificate of Translation Accuracy

Document Translator Date Reviewer
Portuguese ICF v1.0 Maria Silva 06/08/2025 Sunita Reddy

Annexure-3: Consent Process Documentation Log

Date Subject ID Consent Version Witness (if applicable) PI/CRC Signature
15/08/2025 BRA-201 ICF v1.0 (Portuguese) João Pereira Dr. Ana Costa

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
28/08/2025 1.0 Initial SOP for Portuguese consent and cultural/ethical considerations. New SOP created for compliance with ANVISA and CONEP requirements. Head of Clinical Research

For more SOPs visit: Pharma SOP.

ANVISA — Unique SOPs, SOP for GCP Tags:ANVISA consent compliance, clinical trial consent governance Brazil, CRO responsibilities consent SOP, cultural safety clinical trials Brazil, informed consent translation Brazil, inspection readiness consent SOP Brazil, patient comprehension SOP Brazil, Portuguese consent SOP, Portuguese patient information sheet SOP, regulatory submissions ANVISA SOP, SOP for back-translation ICF, SOP for bilingual trial documents Brazil, SOP for consent QA review, SOP for cultural considerations Brazil, SOP for document localization Brazil, SOP for ethics submissions Brazil, SOP for informed consent narratives Brazil, SOP for Portuguese ICFs, SOP for site investigator consent, SOP for sponsor obligations consent Brazil, SOP for subject re-consent Brazil, SOP for subject-facing documents Brazil, SOP for translation vendor governance Brazil, subject comprehension SOP Brazil, trial consent bilingual SOP

Post navigation

Previous Post: Case Studies of Critical CRO Deviations Leading to Regulatory Action
Next Post: Patient Advocacy and Trial Transparency

Quick Guide – 1

  • Clinical Trial Phases (7)
    • Preclinical Studies (25)
    • Phase 0 (Microdosing Studies) (6)
    • Phase 1 (Safety and Dosage) (66)
    • Phase 2 (Efficacy and Side Effects) (54)
    • Phase 3 (Confirmation and Monitoring) (70)
    • Phase 4 (Post-Marketing Surveillance) (79)
  • Regulatory Guidelines (71)
    • U.S. FDA Regulations (14)
    • CDSCO (India) Guidelines (11)
    • EMA (European Medicines Agency) Guidelines (17)
    • PMDA (Japan) Guidelines (1)
    • MHRA (UK) Guidelines (1)
    • TGA (Australia) Guidelines (1)
    • Health Canada Guidelines (1)
    • WHO Guidelines (1)
    • ICH Guidelines (12)
    • ASEAN Guidelines (11)
  • Country-Specific Clinical Trials (254)
    • Clinical Trials in USA (51)
    • Clinical Trials in China (49)
    • Clinical Trials in EU (51)
    • Clinical Trials in India (51)
    • Clinical Trials in UK (51)
    • Clinical Trials in Canada (1)
  • Clinical Trial Design and Protocol Development (106)
    • Randomized Controlled Trials (RCTs) (11)
    • Adaptive Trial Designs (10)
    • Crossover Trials (10)
    • Parallel Group Designs (11)
    • Factorial Designs (11)
    • Cluster Randomized Trials (11)
    • Single-Arm Trials (10)
    • Open-Label Studies (11)
    • Blinded Studies (Single, Double, Triple) (11)
    • Non-Inferiority and Equivalence Trials (8)
    • Randomization Techniques in Crossover Trials (1)
  • Good Clinical Practice (GCP) and Compliance (78)
    • GCP Training Programs (11)
    • ICH-GCP Compliance (11)
    • GCP Violations and Audit Responses (11)
    • Monitoring Plans (11)
    • Investigator Responsibilities (11)
    • Sponsor Responsibilities (11)
    • Ethics Committee Roles (11)
  • Clinical Research Operations (44)
    • Study Start-Up Activities (9)
    • Site Selection and Initiation (10)
    • Patient Enrollment Strategies (13)
    • Data Collection and Management (10)
    • Monitoring and Auditing (1)
    • Study Close-Out Procedures (0)
  • Site Management and Monitoring (72)
    • Site Feasibility Assessments (20)
    • Site Initiation Visits (10)
    • Routine Monitoring Visits (10)
    • Source Data Verification (12)
    • Site Close-Out Visits (10)
    • Site Performance Metrics (10)
  • Contract Research Organizations (CROs) (55)
    • Full-Service CROs (11)
    • Functional Service Providers (FSPs) (10)
    • Niche/Specialty CROs (11)
    • CRO Selection Criteria (11)
    • CRO Oversight and Management (11)
  • Patient Recruitment and Retention (57)
    • Recruitment Strategies (11)
    • Retention Strategies (11)
    • Patient Engagement Tools (11)
    • Diversity and Inclusion in Trials (11)
    • Use of Social Media for Recruitment (12)
  • Informed Consent and Ethics Committees (54)
    • Informed Consent Process (11)
    • Ethics Committee Submissions (10)
    • Ethical Considerations in Vulnerable Populations (11)
    • Consent in Emergency Research (10)
    • Re-Consent Procedures (11)
  • Decentralized Clinical Trials (DCTs) (55)
    • Remote Patient Monitoring (10)
    • Telemedicine in Trials (11)
    • Home Health Visits (11)
    • Direct-to-Patient Drug Delivery (11)
    • Digital Consent Platforms (11)
  • Clinical Trial Supply and Logistics (55)
    • Investigational Product Management (11)
    • Cold Chain Logistics (10)
    • Supply Chain Risk Management (11)
    • Labeling and Packaging (11)
    • Return and Destruction of Supplies (11)
  • Safety Reporting and Pharmacovigilance (56)
    • Adverse Event Reporting (11)
    • Serious Adverse Event (SAE) Management (11)
    • Safety Signal Detection (11)
    • Risk Management Plans (11)
    • Periodic Safety Update Reports (PSURs) (11)
  • Clinical Data Management (57)
    • Case Report Form (CRF) Design (11)
    • Data Entry and Validation (11)
    • Query Management (11)
    • Database Lock Procedures (11)
    • Data Archiving (12)
  • Biostatistics in Clinical Research (57)
    • Statistical Analysis Plans (11)
    • Sample Size Determination (11)
    • Interim Analysis (11)
    • Survival Analysis (12)
    • Handling Missing Data (11)
  • Real-World Evidence (RWE) and Observational Studies (56)
    • Registry Studies (11)
    • Retrospective Chart Reviews (11)
    • Prospective Cohort Studies (11)
    • Case-Control Studies (11)
    • Use of Electronic Health Records (EHRs) (11)
  • Medical Writing and Study Documentation (58)
    • Protocol Writing (11)
    • Investigator Brochures (11)
    • Clinical Study Reports (CSRs) (11)
    • Manuscript Preparation (11)
    • Regulatory Submission Documents (13)
  • Trial Master File (TMF) Management (57)
    • TMF Structure and Contents (10)
    • Electronic TMF Systems (7)
    • TMF Quality Control (12)
    • Inspection Readiness (12)
    • Archiving Requirements (11)
  • Protocol Amendments and Version Control (45)
    • Amendment Classification (11)
    • Regulatory Submissions of Amendments (11)
    • Communication of Changes to Sites (11)
    • Version Control Systems (11)
  • Data Integrity and ALCOA+ Principles (46)
    • Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA) (12)
    • Complete, Consistent, Enduring, and Available (ALCOA+) (10)
    • Data Governance Policies (12)
    • Audit Trails (11)
  • Investigator and Site Training (44)
    • Investigator Meetings (11)
    • Site Staff Training Programs (11)
    • Training Documentation (11)
    • Continuing Education Requirements (10)
  • Budgeting and Financial Management (40)
    • Budget Development (10)
    • Site Payment Management (10)
    • Financial Forecasting (10)
    • Cost Tracking and Reporting (10)
  • AI, Big Data, and Technology in Clinical Trials (41)
    • AI in Patient Recruitment (10)
    • Machine Learning for Data Analysis (10)
    • Blockchain for Data Security (10)
    • Wearable Devices and Sensors (11)
  • Career in Clinical Research (52)
    • Clinical Research Coordinator (CRC) Roles (11)
    • Clinical Research Associate (CRA) Roles (10)
    • Data Manager Careers (10)
    • Biostatistician Roles (10)
    • Regulatory Affairs Careers (11)
  • Clinical Trial Registries and Result Disclosure (40)
    • ClinicalTrials.gov Registration (9)
    • EudraCT Registration (10)
    • Results Posting Requirements (10)
    • Transparency Initiatives (11)

Quick Guide – 2

  • Clinical Trial Operations & Data Integrity (31)
    • TMF & eTMF (10)
    • Study Operations & Enrollment (10)
    • Biostats, CDISC & Traceability (11)
  • Clinical Trial Operations & Compliance (54)
    • Clinical Trial Logistics (30)
    • TMF / eTMF Management (6)
    • Clinical Trial Phases & Design (6)
    • Regulatory Submissions (CTD/eCTD) (6)
    • Vendor Oversight & CRO Compliance (6)
  • Quality Assurance and Audit Management (40)
    • Internal Audits (10)
    • External Audits (10)
    • Audit Preparation (10)
    • Corrective and Preventive Actions (CAPA) (10)
  • Risk-Based Monitoring (RBM) (40)
    • Risk Assessment Tools (10)
    • Centralized Monitoring Techniques (10)
    • Key Risk Indicators (KRIs) (10)
    • Key Risk Indicators (KRIs) (10)
  • Standard Operating Procedures (SOPs) (39)
    • SOP Development (9)
    • SOP Training (10)
    • SOP Compliance Monitoring (10)
    • SOP Revision Processes (10)
  • Electronic Data Capture (EDC) and eCRFs (40)
    • EDC System Selection (10)
    • eCRF Design (10)
    • Data Validation Rules (10)
    • User Access Management (10)
  • Wearables and Digital Endpoints (35)
    • Integration of Wearable Devices (10)
    • Digital Biomarkers (9)
    • Data Collection and Analysis (7)
    • Regulatory Considerations (9)
  • Blockchain and Data Security in Trials (39)
    • Blockchain Applications in Clinical Research (10)
    • Data Encryption Methods (9)
    • Access Control Mechanisms (11)
    • Compliance with Data Protection Regulations (9)
  • Biomarkers and Companion Diagnostics (39)
    • Biomarker Identification (10)
    • Validation Processes (10)
    • Companion Diagnostic Development (9)
    • Regulatory Approval Pathways (10)
  • Pediatric and Geriatric Clinical Trials (55)
    • Ethical Considerations (11)
    • Age-Specific Protocol Design (22)
    • Dosing and Safety Assessments (11)
    • Recruitment Strategies (11)
  • Oncology Clinical Trials (54)
    • Phase-Specific Oncology Trials (10)
    • Immunotherapy Studies (14)
    • Biomarker-Driven Trials (10)
    • Basket and Umbrella Trials (8)
    • Cancer Vaccines (12)
  • Vaccine Clinical Trials (40)
    • Phase I–IV Vaccine Trials (10)
    • Immunogenicity Assessments (10)
    • Cold Chain Requirements (10)
    • Post-Marketing Surveillance (10)
  • Rare and Orphan Disease Trials (186)
    • Patient Recruitment Challenges (31)
    • Regulatory Incentives (10)
    • Adaptive Trial Designs (10)
    • Natural History Studies (10)
    • Regulatory Frameworks (22)
    • Trial Design & Methodology (22)
    • Operational Challenges (21)
    • Ethics & Patient Engagement (20)
    • Data & Technology (20)
    • Case Studies & Breakthroughs (20)
  • Bioavailability and Bioequivalence Studies (BA/BE) (41)
    • Study Design Considerations (11)
    • Analytical Method Validation (10)
    • Statistical Analysis Requirements (10)
    • Regulatory Submission (10)
  • Regulatory Submissions and Approvals (73)
    • IND (Investigational New Drug) Submissions (10)
    • CTA (Clinical Trial Application) (10)
    • NDA/BLA/MAA Filings (10)
    • ANDA for Generics (10)
    • eCTD Submission Process (2)
    • Pre-Submission Meetings (FDA Type A/B/C) (10)
    • Regulatory Query Response Handling (10)
    • Post-Approval Commitments (11)
  • Clinical Trial Transparency and Ethics (60)
    • Trial Disclosure Obligations (10)
    • Result Publication Requirements (10)
    • Ethical Review Standards (10)
    • Open Access Data Sharing (10)
    • Informed Consent Disclosure (10)
    • Ethical Dilemmas in Global Research (10)
  • Protocol Deviation and CAPA Management (50)
    • Major vs Minor Deviations (10)
    • Root Cause Analysis (9)
    • CAPA Documentation (9)
    • Preventive Action Planning (1)
    • Monitoring and Training Based on Deviations (10)
    • Deviation Logs and Tracking Tools (11)
  • Audit Trails and Inspection Readiness (59)
    • TMF and eTMF Audit Trails (10)
    • Audit Trail Reviews in EDC (10)
    • Inspection Preparation Checklists (10)
    • Regulatory Inspection Types (Routine, For-Cause) (10)
    • Responding to Audit Observations (9)
    • Mock Inspections and Readiness Drills (10)
  • Study Feasibility and Site Selection (68)
    • Feasibility Questionnaire Design (10)
    • Site Capability Assessment (11)
    • Historical Performance Review (17)
    • Geographic and Demographic Considerations (10)
    • PI (Principal Investigator) Experience Evaluation (10)
    • Site Activation Planning (10)
  • Outsourcing and Vendor Management (65)
    • Vendor Qualification Process (12)
    • Due Diligence and Risk Assessment (11)
    • Vendor Contract Management (12)
    • KPIs for Vendor Performance (10)
    • Vendor Oversight and Audits (10)
    • Communication and Escalation Plans (10)
  • Remote Monitoring and Virtual Visits (64)
    • Centralized Monitoring Techniques (12)
    • Source Data Review Remotely (12)
    • Virtual Site Visits Protocols (11)
    • eConsent and Remote Data Collection (10)
    • Hybrid Monitoring Models (10)
    • Remote Site Training (9)
  • Laboratory and Sample Management (77)
    • Sample Collection SOPs (10)
    • Sample Labeling and Transport (10)
    • Chain of Custody Documentation (11)
    • Bioanalytical Testing and Storage (15)
    • Central vs Local Labs (11)
    • Laboratory Data Reconciliation (20)
  • Adverse Event Reporting and Management (63)
    • AE vs SAE Differentiation (10)
    • Expedited Reporting Timelines (11)
    • MedDRA Coding of Events (11)
    • AE Data Collection in eCRFs (11)
    • Causality and Severity Assessments (10)
    • Regulatory Reporting Requirements (CIOMS, SUSARs) (10)
  • Interim Analysis and Trial Termination (60)
    • Data Monitoring Committees (DMC) (10)
    • Pre-Specified Stopping Rules (10)
    • Statistical Thresholds for Early Stopping (10)
    • Adaptive Modifications Based on Interim Data (10)
    • Unblinding Protocols (10)
    • Reporting of Early Termination to Regulators (10)

Recent Posts

  • Test
  • Comprehensive Guide to Dental Health Care with Braces
  • Understanding Dental Health Care: Managing Implants Cost Effectively
  • Invisalign Alternatives: Practical Dental Health Care Solutions
  • Practical Guide to Dental Health Care: Managing Braces Effectively

Copyright © 2026 Clinical Research Made Simple.

Powered by PressBook WordPress theme